Genetic and epigenetic changes in lung carcinoma and their clinical implications

Modern Pathology

Volumn 24, Issue 7, 2011, Pages 932-943

  Wen, Jing ^a,b   Fu, Jianhua ^b   Zhang, Wei ^b   Guo, Ming ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

epigenomic alterations; genomic alterations; lung cancer; molecular testing; tumor markers

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MICRORNA; PROTEIN KINASE LKB1; PROTEIN P53;

CANCER DIAGNOSIS; CANCER SURVIVAL; CHROMOSOME ABERRATION; EPIGENETICS; GENE IDENTIFICATION; GENE MUTATION; GENE REARRANGEMENT; GENETIC ANALYSIS; HETEROZYGOSITY LOSS; HISTONE MODIFICATION; LUNG CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

CARCINOMA; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MUTATION;

EID: 79959945851     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.46     Document Type: Review

References (158)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66. (Pubitemid 46148091)
2. Brambilla E, Travis WD, Colby TV, et al. The new world health organization classification of lung tumours. Eur Respir J 2001;18:1059-1068. (Pubitemid 34092881)
3. Alberg AJ, Ford JG, Samet JM, American College of Chest P. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:29S-55S. (Pubitemid 47502798)
4. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010;31:27-36.
5. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450:893-898. (Pubitemid 350231325)
6. Tseng JE, Kemp BL, Khuri FR, et al. Loss of FHIT is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res 1999;59:4798-4803. (Pubitemid 29472879)
7. Mao L, Lee JS, Kurie JM, et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 1997;89:857-862. (Pubitemid 27268450)
8. Sozzi G, Sard L, De Gregorio L, et al. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 1997;57:2121-2123. (Pubitemid 27247024)
9. Wistuba II, Lam S, Behrens C, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997;89:1366-1373. (Pubitemid 27418028)
10. Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, et al. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res 2001;61:1309-1313. (Pubitemid 34292548)
11. Sanchez-Cespedes M, Decker PA, Doffek KM, et al. Increased loss of chromosome 9p21 but not P16 inactivation in primary non-small cell lung cancer from smokers. Cancer Res 2001;61:2092-2096. (Pubitemid 32692032)
12. Marsit CJ, Wiencke JK, Nelson HH, et al. Alterations of 9p in squamous cell carcinoma and adenocarcinoma of the lung: association with smoking, TP53, and survival. Cancer Genet Cytogenet 2005;162: 115-121. (Pubitemid 41423467)
13. Pan H, Califano J, Ponte JF, et al. Loss of heterozygosity patterns provide fingerprints for genetic heterogeneity in multistep cancer progression of tobacco smoke-induced non-small cell lung cancer. Cancer Res 2005;65:1664-1669. (Pubitemid 40478590)
14. Nelson HH, Wiencke JK, Gunn L, et al. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res 1998;58:1804-1807. (Pubitemid 28217450)
15. Hirao T, Nelson HH, Ashok TD, et al. Tobacco smoke-induced DNA damage and an early age of smoking initiation induce chromosome loss at 3p21 in lung cancer. Cancer Res 2001;61:612-615. (Pubitemid 32128623)
16. Grepmeier U, Dietmaier W, Merk J, et al. Deletions at chromosome 2q and 12p are early and frequent molecular alterations in bronchial epithelium and NSCLC of long-term smokers. Int J Oncol 2005;27:481-488.
17. Sharp TV, Al-Attar A, Foxler DE, et al. The chromosome 3p21.3-encoded gene, LIMD1, is a critical tumor suppressor involved in human lung cancer development. Proc Natl Acad Sci USA 2008;105:19932-19937.
18. Yendamuri S, Vaporciyan AA, Zaidi T, et al. 3p22.1 and 10q22.3 deletions detected by fluorescence in situ hybridization (FISH): a potential new tool for early detection of non-small cell lung cancer (NSCLC). J Thorac Oncol 2008;3:979-984.
19. Wrage M, Ruosaari S, Eijk PP, et al. Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin Cancer Res 2009;15:1566-1574.
20. Bepler G, Gautam A, Mcintyre LM, et al. Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J Clin Oncol 2002;20:1353-1360. (Pubitemid 34177442)
21. Tseng RC, Chang JW, Hsien FJ, et al. Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer. Int J Cancer 2005;117:241-247.
22. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol 2007;25:561-570. (Pubitemid 350002964)
23. Hernandez-Boussard TM, Hainaut P. A specific spectrum of P53 mutations in lung cancer from smokers: review of mutations compiled in the IARC P53 database. Environ Health Perspect 1998;106: 385-391. (Pubitemid 28524103)
24. Bartsch H, Hietanen E. The role of individual susceptibility in cancer burden related to environmental exposure. Environ Health Perspect 1996; 104(Suppl 3):569-577. (Pubitemid 26196406)
25. Gealy R, Zhang L, Siegfried JM, et al. Comparison of mutations in the P53 and K-Ras genes in lung carcinomas from smoking and nonsmoking women. Cancer Epidemiol Biomarkers Prev 1999;8:297-302. (Pubitemid 29193900)
26. Zhao Y, Wu D, Xiang X, et al. P53 gene mutations in non-small cell lung cancer detected by polymerase chain reaction single-strand conformation polymorphism analysis. Chin Med Sci J 1999;14: 134-137.
27. Ahrendt SA, Chow JT, Yang SC, et al. alcohol consumption and cigarette smoking increase the frequency of P53 mutations in non-small cell lung cancer. Cancer Res 2000;60:3155-3159. (Pubitemid 30407910)
28. Husgafvel-Pursiainen K, Boffetta P, Kannio A, et al. P53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. Cancer Res 2000;60:2906-2911. (Pubitemid 30395814)
29. Vahakangas KH, Bennett WP, Castren K, et al. P53 and k-ras mutations in lung cancers from former and never-smoking women. Cancer Res 2001;61: 4350-4356. (Pubitemid 32685758)
30. Le Calvez F, Mukeria A, Hunt JD, et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res 2005;65:5076-5083. (Pubitemid 40827316)
31. Steels E, Paesmans M, Berghmans T, et al. Role of P53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a metaanalysis. Eur Respir J 2001;18:705-719. (Pubitemid 33040631)
32. Suzuki H, Kawaguchi T, Hasegawa T, et al. Prognostic impact of P53 protein overexpression in patients with node-negative lung adenocarcinoma. Cancer Lett 2006;237:242-247. (Pubitemid 43777075)
33. Chien WP,Wong RH,Wu TC, et al. Potential increase in the prognostic value of P53 mutation by Pro72 allele in stage I non-small-cell lung cancer. Ann Surg Oncol 2009;16:1918-1924.
34. Kosaka T, Yatabe Y, Onozato R, et al. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 2009;4:22-29.
35. Lim EH, Zhang SL, Li JL, et al. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, P53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J Thorac Oncol 2009;4: 12-21.
36. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of P53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007;25:5240-5247. (Pubitemid 350232256)
37. Cortinovis DL, Andriani F, Livio A, et al. FHIT and P53 status and response to platinum-based treatment in advanced non-small cell lung cancer. Curr Cancer Drug Targets 2008;8:342-348.
38. Yarden Y, Sliwkowski MX. Untangling the Erbb signalling network. Nat Rev 2001;2:127-137. (Pubitemid 33674041)
39. Sequist LV, Bell DW, Lynch TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007;25:587-595. (Pubitemid 350002967)
40. Sharma SV, Settleman J. Erbbs in lung cancer. Exp Cell Res 2009;315:557-571.
41. Greulich H, Chen TH, Feng W, et al. Oncogenic transformation by inhibitor-sensitive and-resistant EGFR mutants. PLoS Med 2005;2:E313.
42. Ji H, Li D, Chen L, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006;9:485-495. (Pubitemid 43832191)
43. Politi K, Zakowski MF, Fan PD, et al. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to downregulation of the receptors. Genes Dev 2006;20: 1496-1510. (Pubitemid 43830656)
44. Zhu CQ, Da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in national cancer institute of Canada clinical trials group study BR21. J Clin Oncol 2008;26:4268-4275.
45. Shih JY, Gow CH, Yang PC. EGFR mutation conferring primary resistance to gefitinib in nonsmall-cell lung cancer. N Engl J Med 2005;353: 207-208.
46. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:E73.
47. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-792. (Pubitemid 40271173)
48. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008;105:2070-2075. (Pubitemid 351439466)
49. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009;10: 281-289.
50. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043. (Pubitemid 46799492)
51. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:20932-20937.
52. Milano A, De Rosa V, Iaffaioli RV, et al. Downstream intracellular effectors of epidermal growth factor receptor as targets for anticancer therapy. Expert Opin Ther Targets 2007;11:771-782. (Pubitemid 46901396)
53. Garcia De Palazzo IE, Adams GP, Sundareshan P, et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 1993;53:3217-3220. (Pubitemid 23223283)
54. Ji H, Zhao X, Yuza Y, et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci USA 2006;103: 7817-7822.
55. Kern JA, Schwartz DA, Nordberg JE, et al. P185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990;50: 5184-5187.
56. Shi D, He G, Cao S, et al. Overexpression of the C-Erbb-2/Neu-encoded P185 protein in primary lung cancer. Mol Carcinog 1992;5:213-218.
57. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005;65: 1642-1646. (Pubitemid 40478587)
58. Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004;431:525-526.
59. Sasaki H, Shimizu S, Endo K, et al. EGFR and Erbb2 mutation status in Japanese lung cancer patients. Int J Cancer 2006;118:180-184. (Pubitemid 41681596)
60. Wang SE, Narasanna A, Perez-Torres M, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006;10:25-38.
61. Al Moustafa AE, Alaoui-Jamali M, Paterson J, et al. Expression Of P185erbb-2, P160erbb-3, P180erbb-4, and heregulin alpha in human normal bronchial epithelial and lung cancer cell lines. Anticancer Res 1999;19:481-486.
62. Muller-Tidow C, Diederichs S, Bulk E, et al. Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res 2005;65:1778-1782. (Pubitemid 40478604)
63. Starr A, Greif J, Vexler A, et al. Erbb4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy. Int J Cancer 2006;119: 269-274.
64. Soung YH, Lee JW, Kim SY, et al. Somatic mutations of the ERBB4 kinase domain in human cancers. Int J Cancer 2006;118:1426-1429.
65. Jeong EG, Soung YH, Lee JW, et al. ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas. Int J Cancer 2006;119:2986-2987.
66. Sasaki H, Okuda K, Kawano O, et al. Erbb4 expression and mutation in Japanese patients with lung cancer. Clin Lung Cancer 2007;8:429-433. (Pubitemid 47242442)
67. Husgafvel-Pursiainen K, Hackman P, Ridanpaa M, et al. K-Ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos. Int J Cancer 1993;53:250-256. (Pubitemid 23042874)
68. Noda N, Matsuzoe D, Konno T, et al. Risk for K-Ras gene mutations in smoking-induced lung cancer is associated with cytochrome P4501A1 and glutathione S-transferase micro1 polymorphisms. Oncol Rep 2004;12:773-779.
69. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346. (Pubitemid 40425952)
70. Soung YH, Lee JW, Kim SY, et al. Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch 2005;446:483-488.
71. Bae NC, Chae MH, Lee MH, et al. EGFR, ERBB2, And KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet Cytogenet 2007; 173:107-113. (Pubitemid 46281348)
72. Slebos RJ, Hruban RH, Dalesio O, et al. Relationship between K-Ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst 1991;83:1024-1027.
73. Westra WH, Slebos RJ, Offerhaus GJ, et al. K-Ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that k-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 1993;72: 432-438. (Pubitemid 23193449)
74. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-Ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001;92: 1525-1530. (Pubitemid 32947838)
75. Suzuki M, Shigematsu H, Iizasa T, et al. Exclusive mutation in epidermal growth factor receptor gene, HER-2, And KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer 2006;106: 2200-2207. (Pubitemid 43673242)
76. Mounawar M, Mukeria A, Le Calvez F, et al. Patterns of EGFR, HER2, TP53, and KRAS mutations of P14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res 2007;67:5667-5672. (Pubitemid 46984998)
77. Puisieux A, Lim S, Groopman J, et al. Selective targeting of P53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res 1991;51:6185-6189.
78. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008;14:5731-5734.
79. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-4689. (Pubitemid 19213607)
80. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007;13:2890-2896. (Pubitemid 46849563)
81. Hezel AF, Bardeesy N. LKB1; linking cell structure and tumor suppression. Oncogene 2008;27: 6908-6919.
82. Sanchez-Cespedes M, Parrella P, Esteller M, et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 2002;62:3659-3662. (Pubitemid 34728843)
83. Carretero J, Medina PP, Pio R, et al. Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene 2004;23:4037-4040. (Pubitemid 38747933)
84. Zhong D, Guo L, De Aguirre I, et al. LKB1 mutation in large cell carcinoma of the lung. Lung Cancer 2006;53:285-294. (Pubitemid 44189563)
85. Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007;448:807-810. (Pubitemid 47266337)
86. Matsumoto S, Iwakawa R, Takahashi K, et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 2007;26: 5911-5918.
87. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer. Nature 2007;448:561-566. (Pubitemid 47206930)
88. Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008;68:4971-4976.
89. McDermott U, Iafrate AJ, Gray NS, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008;68:3389-3395.
90. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-1203. (Pubitemid 350235027)
91. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-4253.
92. Shinmura K, Kageyama S, Tao H, et al. EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, Or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 2008;61:163-169.
93. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALKrearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15:5216-5223.
94. Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010;17:889-897.
95. Martelli MP, Sozzi G, Hernandez L, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009; 174:661-670.
96. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008;3: 13-17.
97. Heller G, Zielinski CC, Zochbauer-Muller S. Lung cancer: from single-gene methylation to methylome profiling. Cancer Metastasis Rev 2010;29:95-107.
98. Kim H, Kwon YM, Kim JS, et al. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J Clin Oncol 2004;22:2363-2370. (Pubitemid 41115393)
99. Liu Y, Lan Q, Siegfried JM, et al. Aberrant promoter methylation of P16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia 2006;8:46-51.
100. Vaissiere T, Hung RJ, Zaridze D, et al. Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res 2009;69:243-252.
101. Buckingham L, Penfield Faber L, Kim A, et al. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer 2010;126:1630-1639.
102. Kaira K, Sunaga N, Tomizawa Y, et al. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers. Int J Oncol 2007;31:169-173.
103. Tessema M, Yu YY, Stidley CA, et al. Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers. Carcinogenesis 2009;30:1132-1138.
104. Lin Q, Geng J, Ma K, et al. RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not P16ink4a, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China. J Cancer Res Clin Oncol 2009;135:1675-1684.
105. Yano M, Toyooka S, Tsukuda K, et al. Aberrant promoter methylation of human DAB2 interactive protein (Hdab2ip) gene in lung cancers. Int J Cancer 2005;113:59-66. (Pubitemid 39507311)
106. Kikuchi S, Yamada D, Fukami T, et al. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer. Clin Cancer Res 2005;11:2954-2961. (Pubitemid 40525198)
107. Chen H, Suzuki M, Nakamura Y, et al. Aberrant methylation of FBN2 in human non-small cell lung cancer. Lung Cancer 2005;50:43-49. (Pubitemid 41297468)
108. Yoshino M, Suzuki M, Tian L, et al. Promoter hypermethylation of the P16 and Wif-1 genes as an independent prognostic marker in Stage IA non-small cell lung cancers. Int J Oncol 2009;35:1201-1209.
109. Suzuki M, Mohamed S, Nakajima T, et al. Aberrant methylation of CXCL12 in non-small cell lung cancer is associated with an unfavorable prognosis. Int J Oncol 2008;33:113-119.
110. Seng TJ, Currey N, Cooper WA, et al. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer 2008;99:375-382.
111. Yanagawa N, Tamura G, Oizumi H, et al. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer 2007;58:131-138. (Pubitemid 47379969)
112. Suzuki M, Hao C, Takahashi T, et al. Aberrant methylation of SPARC in human lung cancers. Br J Cancer 2005;92:942-948. (Pubitemid 40462643)
113. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in Stage I lung cancer. N Engl J Med 2008;358:1118-1128. (Pubitemid 351398486)
114. Ramirez JL, Rosell R, Taron M, et al. 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: the Spanish lung cancer group. J Clin Oncol 2005;23:9105-9112.
115. Wang Y, Yu Z, Wang T, et al. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer 2007;56: 289-294. (Pubitemid 46613917)
116. Grote HJ, Schmiemann V, Geddert H, et al. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer. Cancer 2006;108:129-134.
117. Ulivi P, Zoli W, Calistri D, et al. P16ink4a and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. J Cell Physiol 2006;206: 611-615. (Pubitemid 43191035)
118. Olaussen KA, Soria JC, Park YW, et al. Assessing abnormal gene promoter methylation in paraffinembedded sputum from patients with NSCLC. Eur J Cancer 2005;41:2112-2119. (Pubitemid 41337953)
119. Belinsky SA, Liechty KC, Gentry FD, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006;66:3338-3344.
120. Lin RK, Hsu HS, Chang JW, et al. Alteration of DNA methyltransferases contributes to 50cpg methylation and poor prognosis in lung cancer. Lung Cancer 2007;55:205-213.
121. Lin RK, Hsieh YS, Lin P, et al. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J Clin Invest 2010;120:521-532.
122. Xing J, Stewart DJ, Gu J, et al. Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer. Br J Cancer 2008;98:1716-1722. (Pubitemid 351684678)
123. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007;8:286-298. (Pubitemid 46439286)
124. Barlesi F, Giaccone G, Gallegos-Ruiz MI, et al. Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol 2007;25: 4358-4364. (Pubitemid 350013840)
125. Seligson DB, Horvath S, Mcbrian MA, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 2009;174:1619-1628.
126. Kopelovich L, Crowell JA, Fay JR. The epigenome as a target for cancer chemoprevention. J Natl Cancer Inst 2003;95:1747-1757. (Pubitemid 38008897)
127. Witt O, Deubzer HE, Milde T, et al. HDAC family: what are the cancer relevant targets? Cancer Lett 2009;277:8-21.
128. Sasaki H, Moriyama S, Nakashima Y, et al. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 2004;46:171-178. (Pubitemid 39330411)
129. Bartling B, Hofmann HS, Boettger T, et al. Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma. Lung Cancer 2005;49:145-154. (Pubitemid 40966741)
130. Osada H, Tatematsu Y, Saito H, et al. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer 2004;112:26-32. (Pubitemid 39249488)
131. Kodani M, Igishi T, Matsumoto S, et al. Suppression of phosphatidylinositol 3-kinase/Akt signaling pathway is a determinant of the sensitivity to a novel histone deacetylase inhibitor, FK228, in lung adenocarcinoma cells. Oncol Rep 2005;13:477-483.
132. Yu XD, Wang SY, Chen GA, et al. Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells. Cancer J 2007;13:105-113.
133. Choi YH. Induction of apoptosis by Trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of Cyclooxygenase-2 activity in human non-small cell lung cancer cells. Int J Oncol 2005;27:473-479.
134. Doi S, Soda H, Oka M, et al. The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells. Mol Cancer Ther 2004;3: 1397-1402. (Pubitemid 39562584)
135. Ota H, Tokunaga E, Chang K, et al. Sirt1 inhibitor, sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 2006;25:176-185. (Pubitemid 43083679)
136. Mayo MW, Denlinger CE, Broad RM, et al. Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. J Biol Chem 2003;278:18980-18989. (Pubitemid 36799282)
137. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-866. (Pubitemid 44629897)
138. Liu B, Peng XC, Zheng XL, et al. Mir-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer 2009;66:169-175.
139. Liu X, Sempere LF, Ouyang H, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 2010;120:1298-1309.
140. Cha ST, Chen PS, Johansson G, et al. MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis. Cancer Res 2010;70: 2675-2685.
141. He X, Duan C, Chen J, et al. Let-7a elevates P21(WAF1) levels by targeting of NIRF and suppresses the growth of A549 lung cancer cells. FEBS Lett 2009;583:3501-3507.
142. Crawford M, Batte K, Yu L, et al. MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem Biophys Res Commun 2009;388:483-489.
143. Bandi N, Zbinden S, Gugger M, et al. Mir-15a and Mir-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res 2009;69:5553-5559.
144. Wang G, Mao W, Zheng S. MicroRNA-183 regulates ezrin expression in lung cancer cells. FEBS Lett 2008;582:3663-3668.
145. Crawford M, Brawner E, Batte K, et al. MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun 2008;373: 607-612.
146. Sun Y, Bai Y, Zhang F, et al. Mir-126 inhibits nonsmall cell lung cancer cells proliferation by targeting EGFL7. Biochem Biophys Res Commun 2010;391: 1483-1489.
147. Bishop JA, Benjamin H, Cholakh H, et al. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 2010;16:610-619.
148. Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay based on Hsa-Mir-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009;27:2030-2037.
149. Markou A, Tsaroucha EG, Kaklamanis L, et al. Prognostic value of mature microRNA-21 and micro-RNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 2008;54:1696-1704.
150. Xie Y, Todd NW, Liu Z, et al. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 2010;67:170-176.
151. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the Let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64: 3753-3756. (Pubitemid 38697282)
152. Gallardo E, Navarro A, Vinolas N, et al. Mir-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 2009;30: 1903-1909.
153. Raponi M, Dossey L, Jatkoe T, et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 2009;69:5776-5783.
154. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-198. (Pubitemid 43357945)
155. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008;13:48-57.
156. Hu Z, Chen X, Zhao Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010;28: 1721-1726.
157. Raponi M, Zhang Y, Yu J, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 2006;66:7466-7472. (Pubitemid 44289200)
158. Gazdar AF. Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev 2010;29:37-48.